Provided by Tiger Trade Technology Pte. Ltd.

Ocular Therapeutix

10.62
-0.8500-7.41%
Post-market: 10.830.2100+1.98%19:30 EDT
Volume:2.39M
Turnover:25.74M
Market Cap:2.32B
PE:-7.51
High:11.43
Open:11.43
Low:10.54
Close:11.47
52wk High:16.44
52wk Low:6.23
Shares:218.91M
Float Shares:185.00M
Volume Ratio:1.08
T/O Rate:1.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4140
EPS(LYR):-1.4203
ROE:-72.99%
ROA:-34.95%
PB:4.47
PE(LYR):-7.48

Loading ...

NASDAQ TRADE HALT HALT NEWS PENDING AT 08:40 AM

Reuters
·
Jun 17

Ocular Therapeutix Expands Equity Plan and Confirms Leadership

TIPRANKS
·
Jun 13

Ocular Therapeutix - Appoints Jason Robins as Chief Financial Officer on June 10, 2026 - SEC Filing

THOMSON REUTERS
·
Jun 13

Ocular Therapeutix names Jason Robins CFO, replacing interim role

Reuters
·
Jun 13

Assessing Ocular Therapeutix (OCUL) Valuation After Recent Share Price Weakness

Simply Wall St.
·
Jun 08

BRIEF-Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Jun 05

Ocular Therapeutix grants inducement awards of options for 51,775 shares, RSUs for 16,950 shares to new hires

Reuters
·
Jun 05

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 05

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit 2026

GlobeNewswire
·
Jun 04

Ocular Therapeutix to host investor day with retinal disease experts

Reuters
·
Jun 02

Ocular Therapeutix™ to Host Investor Day on June 17, 2026

GlobeNewswire
·
Jun 02

Ocular Therapeutix Insiders Make a Wave of High-Level Stock Moves

TIPRANKS
·
May 29

Can Ocular Therapeutix's (OCUL) Rising Losses on Flat Revenue Still Support Its R&D Ambitions?

Simply Wall St.
·
May 20

Ocular Therapeutix grants new HR chief options for 75,000 shares, 25,000 RSUs

Reuters
·
May 15

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 15

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
May 15

EyePoint's late-stage eye drug trials to continue after safety panel review

Reuters
·
May 14

A Look At Ocular Therapeutix (OCUL) Valuation After Recent Share Price Pullback

Simply Wall St.
·
May 13

BRIEF-Ocular Therapeutix reports inducement grants under Nasdaq listing rule 5635(C)(4)

Reuters
·
May 09

Ocular Therapeutix grants 12 new hires options for 127,650 shares, RSUs for 41,550 shares

Reuters
·
May 09